Visgenx, a biotechnology firm dedicated to advancing gene therapies for degenerative retinal diseases, has revealed an expansion of its partnership with Charles River Laboratories International, a contract development and manufacturing organization (CDMO). The extended collaboration focuses on VGX-0111, a gene therapy designed by Visgenx for dry age-related macular degeneration (AMD). Following Visgenx's successful Type B pre-IND meeting with the FDA in the summer of 2023, Charles River will commence the manufacturing of materials for VGX-0111. The objective is to initiate a clinical proof-of-concept in 2025. The materials produced by Charles River will facilitate a good laboratory practice (GLP) pre-clinical toxicology study, building on a prior collaboration for adeno-associated virus (AAV) production.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!